Latest Breaking News On - Aiolos bio - Page 7 : comparemela.com

Upcoming Patent Expirations to Drive Biopharma Deals

Upcoming Patent Expirations to Drive Biopharma Deals
themiddlemarket.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themiddlemarket.com Daily Mail and Mail on Sunday newspapers.

William harriesAiolos bioDan lepantoFederal reserveLeerink partnersImago biosciencesPrometheus biosciencesCaraway therapeuticsHarpoon therapeuticsFederal trade commissionBig pharma

Big Pharma targeting smaller companies, with megadeals now out of favor – Indianapolis Business Journal

Indianapolis-based Eli Lilly and Co. and Switzerland-based Novartis were the most active acquirers in the past 12 months, with seven and six deals respectively, according to data compiled by Bloomberg.

Wouter joustraVersanis bioAiolos bio incAmbrx biopharma incInhibrx incSigilon therapeutics incEli lillyAmbrx biopharmaAiolos bioSwitzerland based novartisPoint biopharma globalSigilon therapeutics

Big Pharma Targets Smaller Companies With Megadeals Out of Favor

Big Pharma Targets Smaller Companies With Megadeals Out of Favor
bnnbloomberg.ca - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bnnbloomberg.ca Daily Mail and Mail on Sunday newspapers.

Emma walmsleyWouter joustraAlcon incPfizer incJpmorgan health conferenceEli lilly coSandoz groupHaleon plcAmbrx biopharma incAiolos bio incAmgen incInhibrx incAmbrx biopharmaAiolos bioBiotech deal surge dials up buzzHorizon therapeutics

Big Pharma Targets Smaller Companies With Megadeals Out of Favor

Some drugmakers are doubling down on prescription medicines, shedding businesses they view as peripheral.

Wouter joustraEmma walmsleyEli lilly coAlcon incInhibrx incSandoz groupHaleon plcPfizer incAmbrx biopharma incAiolos bio incAmgen incAmbrx biopharmaAiolos bioHorizon therapeuticsChief executive officer vas narasimhan

GSK projects bright future

Earlier in the decade, GSK was under attack by several hedge funds that believed the company was underperforming and following the wrong strategy.

United kingdomCity ofSmithkline beechamEmma walmsleyInfanrix pediarixRd research developmentBusiness developmentBellus healthNational immunization programs in europeConstant exchangeValley forgeSpecialty medicinesConsumer healthcareCompound annual growth rateConstant exchange ratesSpecialty medicine